Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saredutant versus placebo with escitalopram active control in elderly patients with major depressive disorder
2006-003793-94Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of saredutant in major depressive disorder (MDD) (3 arms), sponsored by Sanofi. Primary endpoint: Primary efficacy endpoint. Started Aug 2006; status: completed.
02
Drugs
saredutant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2006-003793-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003793-94.